Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Swedbank AB

Swedbank AB reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 2.8% during the 3rd quarter, Holdings Channel reports. The fund owned 109,409 shares of the company’s stock after selling 3,101 shares during the quarter. Swedbank AB’s holdings in Teva Pharmaceutical Industries were worth $1,972,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of TEVA. New Covenant Trust Company N.A. acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at $28,000. UMB Bank n.a. raised its stake in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after buying an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at $48,000. Smithfield Trust Co raised its stake in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares in the last quarter. Finally, Byrne Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at $52,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $16.57 on Thursday. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 52-week low of $9.35 and a 52-week high of $19.31. The business’s 50-day moving average price is $17.60 and its 200 day moving average price is $17.35. The firm has a market cap of $18.77 billion, a P/E ratio of -19.49, a P/E/G ratio of 1.30 and a beta of 0.87.

Insider Buying and Selling

In related news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on TEVA shares. UBS Group raised their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays lifted their target price on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.